Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
Nkarta, Inc. (NKTX)
Company Research
Source: GlobeNewswire
First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2 expected to initiate by year-end 2024 Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025No further NKX019 development in lymphoma planned Platform prioritized to focus on advancement of NKX019 for multiple autoimmune diseases Cash balance of $405.3 million on September 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the third quarter ended September 30, 2024. "We’re encouraged by the early progress that we’ve made in the clinical investigation of NKX019 for autoimmune disease,” said Paul J. Hastings, CEO of Nk
Show less
Read more
Impact Snapshot
Event Time:
NKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTX alerts
High impacting Nkarta, Inc. news events
Weekly update
A roundup of the hottest topics
NKTX
News
- Nkarta to Participate in an Upcoming Investor ConferenceGlobeNewswire
- Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at HC Wainwright from $22.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at Needham & Company LLC from $13.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth [Yahoo! Finance]Yahoo! Finance
- Nkarta, Inc. (NASDAQ: NKTX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.MarketBeat
NKTX
Earnings
- 8/13/24 - Beat
NKTX
Sec Filings
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- 11/7/24 - Form 10-Q
- NKTX's page on the SEC website